Page 31 - ARNM-2-3

Advances in Radiotherapy
& Nuclear Medicine QC parameters in radiopharmaceuticals

contamination restrictions. It should be emphasized that References
if a product contains pyrogens and there are no means to 1. Molavipordanjani S, Hosseinimehr SJ. Fundamental
render it apyrogen, it should be rejected.
concepts of radiopharmaceuticals quality controls. Pharm
9. Conclusion Biomed Res. 2018;4(3):1-8.
doi: 10.18502/pbr.v4i3.538
The biological quality control aspects of
radiopharmaceuticals described above will be valuable 2. Lindsley CW, Müller CE, Bongarzone S. Diagnostic
references for various radiopharmaceutical manufacturers and therapeutic radiopharmaceuticals. J Med Chem.
and quality control testing laboratories. However, 2022;65(19):12497-12499.
radiopharmaceutical manufacturers also understand doi: 10.1021/acs.jmedchem.2c01403
the need for biological quality control as the main 3. Mora-Román JJ, Esquivel-Álvarez A, Quesada-Morales E,
challenge in maintaining quality for parametric release, et al. Radiopharmaceuticals: A mini review of applications
as a patient’s life could be in danger or compromised if and innovations on nuclear medicine. World J Pharm Res.
the radiopharmaceutical formulations are not sterile or 2021;10(13):64-79.
pyrogen-free. The concept of parametric release can be doi: 10.20959/wjpr202113-22132
applied to eliminate or minimize different kinds of testing
on the finished product before its intended use due to 4. Sharma N, Kaur H, Sharma RK. Radiopharmaceuticals
the short half-life of the radionuclide moiety. Time and regulations: Current scenario and the way forward. Appl
Clin Res Clin Trials Regul Affairs. 2017;4:1-12.
resource savings are among the most evident advantages
of parametric release. It is debatable if improved doi: 10.2174/2213476X04666170410141155
sterility assurance will result from developing process 5. Kaushik D, Jangra P, Verma R, et al. Radiopharmaceuticals:
understanding for deploying a parametric release process. An insight into the latest advances in medical uses and
regulatory perspectives. J Biosci. 2021;46:27.
Acknowledgments
doi: 10.1007/s12038-021-00147-5
None. 6. Meher BR. Inclusion of radiopharmaceuticals in the
Indian pharmacopeia: A step forward. Indian J Nucl Med.
Funding 2020;35(1):1-3.
None. doi: 10.4103/ijnm.IJNM_133_19
Conflict of interest 7. Indian Pharmacopoeia. Available from: https://ipc.gov.
in/mandates/indian/pharmacopoeia/about-ip.html [Last
The authors declare that they have no conflicts of interest. accessed on 2023 Nov 20].
Author contributions 8. Thota P, Thota A, Pandey MK, et al. A comparative study
of pharmacopoeial quality standards and regulations of
Conceptualization: Prasad Thota, Bhavna Kumari, Anil radiopharmaceuticals. Indian J Nucl Med. 2021;36:153-162.
Kumar Teotia doi: 10.4103/ijnm.ijnm_222_20
Writing-original draft: Prasad Thota, Bhavna Kumari,
Sachin Kumar, Rakesh Kumar Sharma 9. Radiopharmaceutical Preparations, Indian Pharmacopoeia.
th
Writing-review & editing: Prasad Thota, Bhavna Kumari, 9 ed. Ghaziabad: Indian Pharmacopoeia Commission;
Anil Kumar Teotia, Manoj Kumar Pandey, Bikash 2022.
Medhi, Rakesh Kumar Sharma, Rajeev Singh 10. Radiopharmaceutical Preparations, British Pharmacopeia;
Raghuvanshi 2023.
11. Radiopharmaceutical Preparations, European Pharmacopeia.
Ethics approval and consent to participate Version 11.0; 2023.
Not applicable. 12. Radiopharmaceutical Preparations, United States
Pharmacopeia. Rockville, MD: The United States
Consent for publication Pharmacopoeial Convention; 2022.
Not applicable. 13. Radiopharmaceuticals, the International Pharmacopoeia.
11 ed. Geneva: World Health Organization; 2023.
th
Availability of data
14. Radiopharmaceutical Preparations, Chinese Pharmacopoeia;
Not applicable. 2015.

Volume 2 Issue 3 (2024) 11 doi: 10.36922/arnm.3619